A new study conducted bythe Canadian Concussion Centre and Dr. Charles Tator has shown that Iris Technologies' Non-LCD E-Paper Technology can decrease the risk of exacerbating symptoms in sufferers of post-concussion syndrome (PCS).

US FDA unveiled its Digital Health Innovation Action Plan last week, including a Software Pre-Certification Pilot Program to facilitate faster market access for digital health products.

BIO Investor Forum, an international biotech investor conference focused on early and established private companies, is now accepting applications to present at the October 17-18, 2017 event in San Francisco.

In partnership with Global Affairs Canada, Ontario's Ministry of International Trade is organizing a Health Trade Mission to Japan and Korea, targeting business opportunities in these two important markets.

Jumpstarter is a first-of-its-kind startup event that unites and empowers Hong Kong’s hottest startup sectors.

OBIO member company Steadiwear Inc. took home the titles of "Most Innovative Start-up” in the Wearables/IOT/EduTech  Pitch Competition, and the “Most Favorable Startup”, as decided by audience votes, which earned them a spot in the Grand Finale.

Intronix Technologies will be launching "Myoguide DOC", a comprehensive software package designed to help clinicians who inject Botulinum Toxins, such as Botox®, Dysport® and Xeomin® to manage their patient's spasticity and pain.

Mirexus Biotechnologies Inc. (Mirexus) is excited to announce that it has closed an investment round of $12 million.  Mirexus is a safe and natural nanomaterials company based in Guelph, Ontario that is commercializing PhytoSpherixTM, a novel technology based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to applications in human health.  The funds will be used to finance a factory to produce PhytoSpherixTM, and to fund at least three years of operations as the company grows.

Norgen Biotek Corp., an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acid and protein purification and stabilization, today announced the recent launch of their new portfolio of product and service solutions for Next Generation Sequencing (NGS) applications.  Norgen has extensive experience with NGS, and has leveraged this expertise to develop a number of new kits and workflows for NGS applications.

Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz has been appointed to the company’s Clinical Advisory Board (CAB).

A newly published study provides further data showing Straticyte offers better predictive insight over histopathological dysplasia grading for oral potentially malignant lesion assessment.

KA Imaging, a 2016 CAAP Company, is one of the first three companies to receive funding via FACIT's new Prospects Oncology Fund.

The Biotech Showcase is an investor partnering conference devoted to offering private and public biotechnology and life sciences companies an opportunity to present to and meet with investors and pharma executives.  

Last week, the Government of Canada launched the Strategic Innovation Fund, a new $1.26-billion business investment program. 

The Health IT Canadian Technology Accelerator in the US is accepting applications for fall 2017.

The Canadian Technology Accelerator helps high-potential, high-growth Canadian technology SMEs seeking to expand to the US through a program of workshops, events, mentorship and business introductions.

BlueOceanNutraSciences Inc. (TSXV:BOC) announced that it has received a Natural Products Number (NPN) from Health Canada for its extended release Omega-3 astaxanthin shrimp oil tablets (“XR tablets”), the World’s first Omega-3 oils in XR tablet form.

The Company’s shrimp oil XR tablets were developed by its joint venture partner, CMAX Technologies Inc. (“CMAX”).

Stéphane Gagné, President and CEO of Ovensa Inc - a CAAP alumni - attended BIO 2017 and contributed this report on the value of the conference to Ontario’s life sciences industry.

ScarX Therapeutics, an OBIO CAAP program alumni, announced today it has completed enrollment for its initial human clinical trial of SCX-001, a first-of-its-kind topical treatment to significantly reduce surgical scarring.

Application deadline: August 10th, 2017 - APPLY HERE

Apply now if you are interested in meeting one-on-one with Forbion Capital Partners, after their "Investor Spotlight" presentation at JLabs on September 6th, 2017.